These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Real-World Evidence on Disparities on the Initiation of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome. Yildirim M; Mueller-Hennessen M; Milles BR; Biener M; Hund H; Frey N; Giannitsis E; Salbach C J Am Heart Assoc; 2023 Aug; 12(16):e030879. PubMed ID: 37581388 [TBL] [Abstract][Full Text] [Related]
8. Ticagrelor Utilization in Patients With Non-ST Elevation Acute Coronary Syndromes in Romania. Cotoban AG; Udroiu CA; Vinereanu D Am J Ther; 2021 Apr; 28(3):e271-e283. PubMed ID: 33852478 [TBL] [Abstract][Full Text] [Related]
9. Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome. Bonello L; Laine M; Camoin-Jau L; Noirot F; Guieu R; Dignat-George F; Paganelli F; Frere C Thromb Haemost; 2015 Oct; 114(4):702-7. PubMed ID: 26311415 [TBL] [Abstract][Full Text] [Related]
12. Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis. Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Fleeman N; McEntee J; Dundar Y; Richardson M; Fisher M Health Technol Assess; 2015 Apr; 19(29):1-130. PubMed ID: 25896573 [TBL] [Abstract][Full Text] [Related]
13. Comparison of Ticagrelor Versus Prasugrel for Inflammation, Vascular Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Requiring Coronary Stenting: A Prospective, Randomized, Crossover Trial. Jeong HS; Hong SJ; Cho SA; Kim JH; Cho JY; Lee SH; Joo HJ; Park JH; Yu CW; Lim DS JACC Cardiovasc Interv; 2017 Aug; 10(16):1646-1658. PubMed ID: 28838475 [TBL] [Abstract][Full Text] [Related]
14. Comparison of prescription rates and clinical outcomes in acute coronary syndrome patients who underwent percutaneous coronary intervention using different P2Y Choe JC; Cha KS; Ahn J; Park JS; Lee HW; Oh JH; Choi JH; Lee HC; Hong TJ; Jeong MH; Int J Cardiol; 2019 Jan; 274():21-26. PubMed ID: 30224257 [TBL] [Abstract][Full Text] [Related]
15. Comparison of prasugrel and ticagrelor in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A meta-analysis of randomized and non-randomized studies. Watti H; Dahal K; Zabher HG; Katikaneni P; Modi K; Abdulbaki A Int J Cardiol; 2017 Dec; 249():66-72. PubMed ID: 29121759 [TBL] [Abstract][Full Text] [Related]
16. Meta-Analysis Comparing P2Y Baldetti L; Melillo F; Moroni F; Gallone G; Pagnesi M; Venuti A; Beneduce A; Calvo F; Gramegna M; Godino C; D'Ascenzo F; De Ferrari GM; Capodanno D; Cappelletti AM Am J Cardiol; 2020 Jun; 125(12):1815-1822. PubMed ID: 32305225 [TBL] [Abstract][Full Text] [Related]
17. Downstream or upstream administration of P2Y12 receptor blockers in non-ST elevated acute coronary syndromes: study protocol for a randomized controlled trial. Tarantini G; Mojoli M; Varbella F; Caporale R; Rigattieri S; Andò G; Cirillo P; Pierini S; Santarelli A; Sganzerla P; De Cesare N; Limbruno U; Lupi A; Ricci R; Cernetti C; Favero L; Saia F; Roncon L; Gasparetto V; Ferlini M; Ronco F; Ferri L; Trabattoni D; Russo A; Guiducci V; Penzo C; Tarantino F; Mauro C; Marchese A; Castiglioni B; La Manna A; Martinato M; Gregori D; Angiolillo DJ; Musumeci G Trials; 2020 Nov; 21(1):966. PubMed ID: 33234137 [TBL] [Abstract][Full Text] [Related]